Go Pro
NASDAQ:MIST

Milestone Pharmaceuticals Q2 2026 Earnings Report

Milestone Pharmaceuticals logo
$1.18 0.00 (0.00%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$1.22 +0.04 (+3.12%)
As of 04:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Milestone Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.18
Beat/Miss
N/A
One Year Ago EPS
N/A

Milestone Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Milestone Pharmaceuticals Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Monday, August 10, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

Milestone Pharmaceuticals Earnings Headlines

This same-day trade is getting a lot of attention
Zero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong. Dave Aquino's 0DTE Playbook breaks down a step-by-step strategy designed for shorter risk exposure, clear entry and exit windows, and faster feedback - no chart-watching required.tc pixel
Milestone Pharmaceuticals: Taking The Long View
See More Milestone Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Milestone Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Milestone Pharmaceuticals and other key companies, straight to your email.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals (NASDAQ:MIST), Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs. Preclinical and early clinical studies are aimed at demonstrating safety, tolerability and proof of concept in patient populations with high unmet medical need. The company leverages strategic collaborations and research partnerships to accelerate development and expand its scientific expertise.

Founded in the United States and headquartered in San Diego, California, Milestone Pharmaceuticals operates with a management team experienced in respiratory drug development. The company continues to pursue regulatory pathways for its lead programs and is preparing for later-stage clinical trials. Through a combination of internal innovation and external partnerships, Milestone seeks to bring new treatment options to patients suffering from debilitating respiratory disorders.

View Milestone Pharmaceuticals Profile